Axiogenesis announced today that it will be collaborating with Metrion Biosciences to validate, optimise and commercialise iPSC-derived cell based assays to facilitate drug discovery and more accurately predict cardiac arrhythmia and neuronal risk. Metrion Biosciences a UK-based contract research organization (CRO) that is best known as an ion channel specialist.
Through this strategic partnership, Axiogenesis continues to strengthen its position within the iPS cell marketplace as a leading provider of cell-based solutions to facilitating drug discovery, safety, and toxicology applications. To learn more, see the full press release, included below with permission from Axiogenesis.
Axiogenesis is a fascinating company specializing in the development of induced pluripotent stem cells (iPSCs) and tissue types. It is the second largest iPSC company in the world after Cellular Dynamics International (CDI), in Madison, Wisconsin.
Axiogenesis was also the first European company to license and adopt Yamanaka’s iPSC technology in 2010. The company now specializes in human induced pluripotent stem cell (hiPSC) products, including in vitro models of healthy and diseased cell types and tissues.